dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Vivanco-Hidalgo, Rosa M. |
dc.contributor.author | Martinez, Elisenda |
dc.contributor.author | Roman-Viñas, Ramón |
dc.contributor.author | Sánchez Montalvá, Adrián |
dc.contributor.author | Fibla, Joan |
dc.contributor.author | Molina Romero, Israel |
dc.date.accessioned | 2021-07-19T12:58:51Z |
dc.date.available | 2021-07-19T12:58:51Z |
dc.date.issued | 2021-03-04 |
dc.identifier.citation | Vivanco-Hidalgo RM, Molina I, Martinez E, Roman-Viñas R, Sánchez-Montalvá A, Fibla J, Pontes C, Velasco Muñoz C; Real World Data Working Group. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. Euro Surveill. 2021 Mar;26(9):2001202. |
dc.identifier.issn | 1025-496X |
dc.identifier.uri | https://hdl.handle.net/11351/6182 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cloroquina; Hidroxicloroquina |
dc.description.sponsorship | No funding was obtained for this study. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication. |
dc.language.iso | eng |
dc.publisher | European Centre for Disease Prevention and Control |
dc.relation.ispartofseries | Eurosurveillance;26(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Catalunya |
dc.subject | Medicaments antivírics - Efectes secundaris |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Incidence |
dc.subject.mesh | Antiviral Agents |
dc.subject.mesh | /adverse effects |
dc.title | Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2807/1560-7917.ES.2021.26.9.2001202 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | incidencia |
dc.subject.decs | antivíricos |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.9.2001202 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Vivanco-Hidalgo RM, Martinez E, Roman-Viñas R] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain. [Molina I, Sánchez-Montalvá A] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fibla J] Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain. Institut de Recerca Biomedica de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain |
dc.identifier.pmid | 33663646 |
dc.identifier.wos | 000626069000003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |